Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GTE Gran Tierra Energy	$8.16 +2.1%	$0.00	$4.62 ▼ $8.85	$263.73M	1.62	413,533 shs	515,901 shs
NVA NuVista Energy	C$12.34 +2.2%	C$11.58	C$9.59 ▼ C$13.72	C$2.56B	2.85	425,624 shs	268,340 shs
SQZ SQZ Biotechnologies	$0.05	$0.05	$0.25 ▼ $3.56	$1.42M	2.34	455,220 shs	44,803 shs

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GTE Gran Tierra Energy	0.00%	0.00%	0.00%	0.00%	-99.14%
NVA NuVista Energy	-1.31%	-2.74%	+3.60%	+13.11%	+2.63%
SQZ SQZ Biotechnologies	0.00%	+7.07%	+3.63%	+11.11%	-99.25%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GTE Gran Tierra Energy	1.1602 of 5 stars	2.0	5.0	0.0	0.0	3.3	0.0	0.6
NVA NuVista Energy	2.7382 of 5 stars	2.4	0.0	1.7	0.0	1.9	2.5	2.5
SQZ SQZ Biotechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GTE Gran Tierra Energy	2.00	Hold	$10.00	22.55% Upside
NVA NuVista Energy	2.78	Moderate Buy	C$14.92	20.88% Upside
SQZ SQZ Biotechnologies	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest NVA, OPHR, GTE, GENL, and SQZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/19/2024	NVA NuVista Energy	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform	C$14.00 ➝ C$15.00
4/9/2024	NVA NuVista Energy	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	C$17.00
3/22/2024	NVA NuVista Energy	Desjardins Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	C$15.00 ➝ C$14.75
3/13/2024	GTE Gran Tierra Energy	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$9.00 ➝ $10.00
3/4/2024	NVA NuVista Energy	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target		C$14.25 ➝ C$14.50
3/1/2024	NVA NuVista Energy	CIBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform	C$15.00 ➝ C$15.50
2/27/2024	NVA NuVista Energy	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy	C$13.00
1/19/2024	NVA NuVista Energy	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform	C$18.00 ➝ C$14.50

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GTE Gran Tierra Energy	$636.96M	0.41	$6.74 per share	1.21	$12.29 per share	0.66
NVA NuVista Energy	C$1.26B	2.03	N/A	N/A	C$10.19 per share	1.21
SQZ SQZ Biotechnologies	$18.16M	0.08	N/A	N/A	$1.94 per share	0.02

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GTE Gran Tierra Energy	-$6.29M	-$0.20	N/A	∞	N/A	-0.99%	-1.60%	-0.47%	4/30/2024 (Estimated)
NVA NuVista Energy	C$367.68M	C$1.65	7.48	∞	0.59	29.12%	18.16%	10.71%	5/14/2024 (Estimated)
SQZ SQZ Biotechnologies	-$79.46M	-$2.61	N/A	N/A	N/A	-369.96%	-119.83%	-59.90%	N/A

Latest NVA, OPHR, GTE, GENL, and SQZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/29/2024	Q4 2023	NVA NuVista Energy	C$0.49	C$0.41	-C$0.08	C$0.41	C$364.00 million	C$365.50 million
2/20/2024	12/31/2023	GTE Gran Tierra Energy	-$0.10	$0.23	+$0.33	$0.23	N/A	$154.94 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GTE Gran Tierra Energy	N/A	N/A	N/A	N/A	N/A
NVA NuVista Energy	N/A	N/A	N/A	N/A	N/A
SQZ SQZ Biotechnologies	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GTE Gran Tierra Energy	1.31	0.43	0.32
NVA NuVista Energy	14.42	1.04	0.78
SQZ SQZ Biotechnologies	N/A	3.50	3.50

Ownership

Institutional Ownership

Company	Institutional Ownership
GTE Gran Tierra Energy	31.70%
NVA NuVista Energy	24.73%
SQZ SQZ Biotechnologies	38.51%

Insider Ownership

Company	Insider Ownership
GTE Gran Tierra Energy	6.45%
NVA NuVista Energy	22.89%
SQZ SQZ Biotechnologies	16.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
GTE Gran Tierra Energy	351	32.32 million	30.23 million	Not Optionable
NVA NuVista Energy	88	207.58 million	N/A	Not Optionable
SQZ SQZ Biotechnologies	53	29.49 million	24.77 million	Not Optionable

NVA, OPHR, GTE, GENL, and SQZ Headlines

Source	Headline
	VC funding update: who raised money in March? bizjournals.com - April 1 at 11:06 AM
	SQZ, Portal founder Armon Sharei on starting over in biotech biopharmadive.com - March 26 at 10:35 AM
	Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC finance.yahoo.com - March 19 at 10:20 AM
	SQZ, months after 80% layoffs, opts for liquidation and $11.8M asset fire sale to Stemcell fiercebiotech.com - March 1 at 10:56 AM
	Rx Rundown: Gilead Sciences, Latigo Biotherapeutics, Exscientia and more mmm-online.com - February 16 at 8:05 AM
	SQZB SQZ Biotechnologies Company seekingalpha.com - December 28 at 1:42 PM
	SQZ Biotechnologies Co Ordinary Shares SQZB morningstar.com - December 12 at 8:37 PM
	SQZ founder Armon Sharei opens Portal to to simplify intracellular delivery fiercebiotech.com - December 12 at 10:35 AM
	'Medicine at a bigger scale': FUJIFILM Diosynth Biotechnologies unveils new Holly Springs drug manufacturing site wral.com - November 11 at 8:41 PM
	‘Difficult but necessary steps’: SQZ lays off 80% of staff, RegenXBio cuts 15% fiercebiotech.com - November 9 at 10:34 AM
	SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates finance.yahoo.com - November 8 at 6:33 PM
	SQZ Biotechnologies GAAP EPS of -$0.80 misses by $0.30, revenue of $0M msn.com - November 8 at 6:33 PM
	Lifeline Biotechnologies Inc LLBO morningstar.com - November 4 at 11:41 PM
	SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting finance.yahoo.com - November 3 at 7:42 PM
	SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates finance.yahoo.com - August 10 at 9:16 PM
	Sqz Biotechnologies Co (SQZB) investing.com - August 3 at 7:45 AM
	Roche declines to take up option on SQZ Bio’s SQZ-APC-HPV program thepharmaletter.com - July 27 at 12:11 AM
	Roche Passes on Option to Advance Cell Therapy in HPV-Positive Tumors With SQZ Biotechnologies precisionmedicineonline.com - July 25 at 10:53 PM
	Roche Decides Not to Exercise Solid Tumor Option with SQZ biospace.com - July 25 at 10:53 PM
	SQZ Biotechnologies Provides Update on Collaboration with Roche benzinga.com - July 25 at 12:37 PM
	Roche snubs SQZ HPV 16 programme, leaving the beleaguered company in the lurch pharmaceutical-technology.com - July 25 at 12:37 PM
	Understanding the Risks of Investing in SQZ Biotechnologies Company (SQZ) knoxdaily.com - July 5 at 1:10 PM
	SQZ Biotechnologies to be delisted from the NYSE seekingalpha.com - July 3 at 11:23 PM
	NYSE to Commence Delisting Proceedings Against SQZ Biotechnologies Company (SQZ) finance.yahoo.com - July 3 at 6:23 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Gran Tierra Energy

NYSEAMERICAN:GTE

Gran Tierra Energy Inc., together with its subsidiaries, engages in the exploration and production of oil and gas properties in Colombia and Ecuador. The company was founded in 2003 and is headquartered in Calgary, Canada.

NuVista Energy

TSE:NVA

NuVista Energy Ltd., together with its subsidiary, engages in the exploration, development, and production of oil and natural gas reserves in the Western Canadian Sedimentary Basin. The company is involved in the development, delineation, and production of condensate, natural gas liquids, and natural gas reserves. It primarily focuses on the condensate rich Montney formation in the Pipestone and Wapiti areas of the Alberta Deep Basin. The company was incorporated in 2003 and is headquartered in Calgary, Canada.

SQZ Biotechnologies

NYSE:SQZ

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial